Hemogenyx Pharmaceuticals Share Discussion Threads

[tullynessle] 22/12/2019 21:51

I was reading / researching Hemogenyx / Immugenyx tonight and found a number of references.

The following couple of posts may, (or may not be), be worth following-up at some time in the future.

Captured for the BB

[tullynessle] 22/12/2019 21:46

Tweet by Cornell (University) Tech Transfer on Nov 21, 2019 - scroll down at the link.




Cornell Tech Transfer


Cornell Tech Transfer
@Cornell_CTL
·
Nov 21
Cornell startup Hemogenyx Pharmaceuticals PLC has demonstrated that its CDX antibody is potentially a life-saving treatment for sufferers of forms of blood cancer


==================================

Cornell Tech Transfer
@Cornell_CTL
The Center for Technology Licensing
@Cornell
. We manage #technologies from the Ithaca campus,
@WeillCornell
,
@cornell_tech
, and
@CornellAgriTech
in Geneva.

[tullynessle] 22/12/2019 21:43

From the link it appears that the Presentation was uploaded in December 2019 (2019/12), however it could be 12 Aug, 2019.




A NEW ERA
for the modeling of blood and autoimmune diseases and drug development
Advanced Hematopoietic PBMC Chimera – ApbHC

Dr Vladislav Sandler CO-FOUNDER & CHIEF EXECUTIVE OFFICER

Immugenyx

A new era for the modelling of blood / autoimmune diseases and drug development

[Presentation - 7 pages]

[tsmith2] 22/12/2019 19:13

what email add did you use?

[badger60] 22/12/2019 13:23

It certainly will be if Vlad can get phase trials initiated and make inroads into getting the products toward commercialisation.

[tsmith2] 22/12/2019 13:11

I think 2020 will be a big big big year for us

[badger60] 22/12/2019 13:09

My email sent today...,....,"Dear Dr. SandlerCould you please be more circumspect when issuing RNS. Shareholders were given to believe that the CDX deal with "big pharma", was virtually a given, yet we are seemingly no further forward than this time last year, despite RNS rhetoric to the contrary...,..and enjoy a share price which is 50% of the issue price of 2017.Could you confirm that Sir Marc Feldmann is still the Chairman of the company, as his name failed to appear in the contact section of the last RNS.Despite the progress to date Hemogenyx has been a disappointment value wise. Perhaps share price Angel should be doing something more to promote the company.Yours sincerelyXxxx cxcccc(shareholder)"Dr. Sandler's reply...2 hours later!(Quite frankly, I wasn't expecting a reply as it was written out of blunt frustration!)...........and feeling more comfortable now......after Vlad's reply."Dear xxxxx,Thank you for your message.Sir Marc is the Chairman of Hemogenyx.Early stage biotech demands patience. Hemogenyx is doing very well and is on track to meeting its goals. Please follow our announcements.Best regards,Vladik"

[tullynessle] 21/12/2019 21:41

There is an article on Page 12 & 13 of the hard-copy Scottish Daily Mail today entitled "You Little Miracle".

On Page 13 there is a boxed 1/4 page article entitled "How £500,000 therapy helped"

The first paragraph of this article reads:

"CAR T-Cell therapy gives new hope to patients with certain types of blood cancer that fail to respond to other treatments"

I cannot find the article in the Online version of the newspaper, (perhaps others can try).

The articles are included at "Pressreader".




Pressreader

[badger60] 21/12/2019 14:19

.....and if CDX can seemingly do what's written on the box.... as we've been told, then finding external funding shouldn't be a big problem.....I would have thought....

[badger60] 21/12/2019 14:12

The concert party would block any derisory take over bid......Let's hope that Sandler can either reel in big pharma, or find another suitor.

[on target] 21/12/2019 14:06

Funding wise they still had over £1m cash at the end of June which is enough to keep going into Q2 next year without further funding, but clearly to get out of the lab and start doing trials on monkeys etc. as mentioned in the November presentation they are going to need 'globalco' to stump up cash (which has always been the case).

So yes everything hinges on the CDX deal with the globalco, although at the current market cap wouldn't it make more commercial sense for them to just buy Hemogenyx?

Well spotted with Feldmann - maybe he's stepped down to focus on his cannabis venture? Although he is still listed on the website.

[badger60] 21/12/2019 13:32

On Target
I have to agree. I still have faith in the technology. and ok, the projected timing is out.
What's your take on the current state of affairs.(ie the future viability of company)

I also noticed that Prof Marc Feldmann's name was not listed in the last RNS.
It seems to me that, as already mentioned, the (lack of the promised) big pharma CDX deal is the stumbling block.

[on target] 21/12/2019 13:23

I think things may have changed somewhat since then badger!

[badger60] 21/12/2019 13:13

9.38 into the video gives forward looking revenue projections. 2020 looks interesting although 2019 figures are yet to meet expectations. Perhaps there maybe some more anticipated chimeric mouse deals .

[purple11] 20/12/2019 16:57

sadly these conferences only seem to be signalling to the market that hes in need of a new investor,im hoping its more of him playing the hand of the globalco saying he'll go elsewhere if they don't commit to go further.
certainly the market doesn't like it.

realty is hemo are doing the manufacturability tests now and those will conclude shortly.when they rns that the price should temporarily atleast spike up.
if they can pay for the monkey tests then cdx would be a drug ready to go into phase 1 trials.
that must mean theyd be worth more than 5/6m at that stage so I cant see much downside.

just need globalco or another company to pay for the monkey tests.i cant see that being much of a problem once the manuacturablity tests have successfully concluded.ppl keep saying the monkey tests are so expensive.how expensive?

[purple11] 20/12/2019 16:30

he sounds optimistic.

[purple11] 20/12/2019 16:28

Vladislav Sandler

@vmsandler
·
1h


I am getting ready for the #JPM2020 #JPMorgan conference in San Francisco in January. Some say it is a zoo and useless, for me this one promises a lot of already scheduled meetings with potential partners and investors. Suddenly, I am a hot commodity!

[scaramouche1941] 20/12/2019 16:04

@purple11
I do not know. I think that either globalco pays for everything or pays for nothing. Why would they choose monkeys and not pay for manufacturing and clinical trials? It makes no sense. I think that Hemo will either get everything or nothing. If it gets nothing from globalco they will have to raise a lot of money to go forward or look for another partner. Hemo will be in a very strong position as they will have antibody that is fully validated by the globalco though.

[purple11] 20/12/2019 16:03

atleast we can say we bought a turkey for Christmas anyway.

[purple11] 20/12/2019 15:52

why do you think they wont be funding it?

[scaramouche1941] 20/12/2019 15:50

@purple11
Who told you that globalco will fund this?
If that is the case then we are all golden!
I googled “manufacturability tests” in biotech and it seems to be a very complicated set of tests. This is usually what a company does to make sure that a molecule can be manufactured as a drug.

[purple11] 20/12/2019 15:17

m2-3m?

the globalco will be funding the monkey trials as part of its development agreement,or that was what I was led to believe.

[scaramouche1941] 20/12/2019 15:13

@purple11
Monkey trials would be probably toxicity studies and pharmacokinetics or something like that. If they are doing those for the FDA then the price would probably go up to M2-3M. Monkey studies are very expensive. I do not understand how they can do those without raising additional funds

[flashheart] 20/12/2019 12:50

More interesting tweets from Vladislav Sandler. Some re-tweeted.

[purple11] 20/12/2019 09:43

I cant see these manufacturability tests going wrong or taking that long,and well have news on their outcome to come.
then surely they'll be able to get the global pharma company to atleast pay for the monkey trials.

success in the monkey trials will provide a pretty sizeable spike and anyone wishing to exit should wait for that imo.

we need news on when these monkey trials will be starting.i cant see the global pharma company not paying for them,i doubt they cost that much.

this is weak because theres a lull in news and the market is worried about how they will pay for the trial.

a little bit of faith and give it 6months or so and we could be reading about a positive result in monkeys which will clearly spark a rocket here.patience and ignore the price tll then I say.i am reassured by what Adrian b had to say and that he hasn't sold any shares yet.

better days ahead!